Edgar Filing: ANTIGENICS INC /DE/ - Form 4

ANTIGENICS IN	C/DE/									
Form 4										
January 08, 2007										
FORM 4			an aru						PPROVAL	
	UNITED	STATES		RITIES A shington			COMMISSIO	N OMB Number:	3235-0287	
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations	STATEM Filed pur	suant to S	Estimated burden hou response	irs per						
<i>See</i> Instruction 1(b).	Section 17(•	•	npany Act 1y Act of 1	of 1935 or Secti 940	on		
(Print or Type Respon	ises)									
1. Name and Address of Reporting Person <u>*</u> Sharp Shalini			2. Issuer Name and Ticker or Trading Symbol ANTIGENICS INC /DE/ [AGEN]				5. Relationship of Reporting Person(s) to Issuer			
(Last) (I	First) (I	Middle)	3 Date o	of Earliest T	ransaction		(Che	eck all applicabl	e)	
C/O ANTIGENIO FIFTH AVE., SU	CS INC., 63	,		Day/Year)	Tunsuetion		Director X Officer (gi below)		6 Owner er (specify	
(S	Street)			endment, D onth/Day/Yea	-	1	6. Individual or Applicable Line) _X_Form filed by	One Reporting P	erson	
NEW YORK, NY							Form filed by Person	More than One R	eporting	
(City) (S	State)	(Zip)	Tab	le I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
	nsaction Date h/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	Code (Instr. 8)	4. Securit nAcquired Disposed (Instr. 3, 4 Amount	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Pamindar: Danart an	a congrata lina	for each al	ass of acc	urities bore	ficially or	ad directly	or indirectly			
Reminder: Report on	a separate fine	ior each ch	ass of sec	unnes dene	Perso inform requir	ns who rest nation cont ed to respo sys a current	spond to the colle ained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8.1
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	De
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	Sec

Edgar Filing: ANTIGENICS INC /DE/ - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)			Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		((In	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Restricted Stock (1)	\$ 0	01/05/2007		А		16,000		<u>(1)</u>	(1)	Common Stock	16,000	

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Sharp Shalini C/O ANTIGENICS INC. 630 FIFTH AVE., SUITE 2100 NEW YORK, NY 10111			CFO				
Signatures							

Christine M. Klaskin, by Power of Attorney

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

01/08/2007

(1) Restricted Stock granted in accordance with the terms of the Antigenics Inc. 1999 Equity Incentive Plan, as amended, and vests equally over 2 years beginning January 5, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.